Table 1 Characteristics of patients before PMX-DHP therapy
| Â | Survivors | Non-survivors | p value |
|---|---|---|---|
Case No. | 5 | 9 | Â |
Age | 64 (36–75) | 58 (44–77) | 0.546 |
Sex (Male/Female) | 1/4 | 2/7 | 1.000 |
BMI | 22.1 (20.5–24.1) | 22 (20.6–28.6) | 0.548 |
Smoking status (Never/Ex/Current) | 4/1/0 | 7/0/2 | 1.000 |
Days from steroid pulse therapy to PMX-DHP | 5 (1–11) | 6 (1–48) | 0.584 |
Anti-ARS Ab (PL-7/EJ) Anti-MDA-5 Ab | 3 (2/1) 1 | 0 9 | 0.028* 0.005* |
IPPV | 1 | 4 | 0.580 |
Steroid pulse therapy | 5 | 9 | 1.000 |
Immunosuppressive agents | Â | Â | Â |
Cyclosporine | 4 | 8 | 1.000 |
Tacrolimus | 1 | 5 | 0.301 |
Cyclophosphamide pulse | 5 | 9 | 1.000 |